Skip to content
Biodatica
Start free

Gan and Lee Pharmaceuticals, USA

Beijing

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: A Study of GZR18 Injection in Obese/Overweight Patients

9mo agoTrial registeredOct 1, 2025Source filing (opens the source filing in a new tab)

Momentum

56no change

Momentum 56 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,110 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $664k · non-dilutive

    Aug 1, 2024

    EMORY UNIVERSITY · PI QIU, DEQIANG · NIA · award ends Apr 30, 2029 · Explainable and Ethical AI for Studying Alzheimer's Disease

    NIH RePORTER · NIH RePORTER 11142558 (opens the source filing in a new tab)

  2. Grant

    R01 · $350k · non-dilutive

    Apr 1, 2024

    UNIVERSITY OF TEXAS AT AUSTIN · PI CASTILLO, EDWARD · NHLBI · award ends Mar 31, 2028 · CT-Derived Functional Imaging for Predicting Disease Progression in COPD

    NIH RePORTER · NIH RePORTER 11053533 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 8, 2023

    Obesity, Overweight · COMPLETED · sponsor: Gan and Lee Pharmaceuticals, USA · A Study of GZR18 Injection in Obese/Overweight Patients

    ClinicalTrials.gov · NCT06256562 (opens the source filing in a new tab)

  4. Grant

    R35 · $458k · non-dilutive

    Sep 1, 2019

    ROCKEFELLER UNIVERSITY · PI ZHAO, LI · NIGMS · award ends Jun 30, 2029 · The Genetic and Epigenetic Mechanisms of Phenotypic Innovation

    NIH RePORTER · NIH RePORTER 11160464 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources